Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Isodorsmanin A

$780

  • Brand : BIOFRON

  • Catalogue Number : AV-B03015

  • Specification : 97%

  • CAS number : 118266-99-2

  • Formula : C20H20O4

  • Molecular Weight : 324.37

  • PUBCHEM ID : 14078473

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

AV-B03015

Analysis Method

HPLC,NMR,MS

Specification

97%

Storage

2-8°C

Molecular Weight

324.37

Appearance

Yellow powder

Botanical Source

Structure Type

Chalcones

Category

Standards;Natural Pytochemical;API

SMILES

CC1(CCC2=C(C=CC(=C2O1)C(=O)C=CC3=CC=C(C=C3)O)O)C

Synonyms

(2E)-1-(5-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-8-yl)-3-(4-hydroxyphenyl)prop-2-en-1-one/2-Propen-1-one, 1-(3,4-dihydro-5-hydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl)-3-(4-hydroxyphenyl)-, (2E)-/(2E)-1-(5-Hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-8-yl)-3-(4-hydroxyphenyl)-2-propen-1-one/crotmadine

IUPAC Name

(E)-1-(5-hydroxy-2,2-dimethyl-3,4-dihydrochromen-8-yl)-3-(4-hydroxyphenyl)prop-2-en-1-one

Applications

Density

1.2±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

198.7±23.6 °C

Boiling Point

549.9±50.0 °C at 760 mmHg

Melting Point

239-240℃

InChl

InChI=1S/C20H20O4/c1-20(2)12-11-16-18(23)10-8-15(19(16)24-20)17(22)9-5-13-3-6-14(21)7-4-13/h3-10,21,23H,11-12H2,1-2H3/b9-5+

InChl Key

SEDVPKQZRCGYNR-WEVVVXLNSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:118266-99-2) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

31339004

Title

Oral abstracts of the 10th IAS Conference on HIV Science, 21?24 July 2019, Mexico City, Mexico

Publish date

2019 Jul;

PMID

26788114

Abstract

Background
Active metabolism of peripheral blood mononuclear cells (PBMC) could suggest their suitability for metabolomics studies. This study examined whether reductions in PBMCs and plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) activities induced by dietary intervention affected the overall metabolic profiles of PBMC and plasma.

Methods
Eighty nonobese subjects aged 40-70 years (18.5 ≤ BMI < 30 kg/m2) with prediabetes or newly-diagnosed type-2 diabetes were assigned to consume either the usual refined-rice diet (control group, n = 40) or to replace refined rice with whole grains and legumes as carbohydrates (whole-grain group, n = 40) for three meals per day during the 12-week intervention. Fasting PBMC and plasma metabolomes were profiled using UPLC-LTQ-Orbitrap mass spectrometry. Results After 12 weeks, changes in fasting glucose, HbA1c, HOMA-IR, MDA, ox-LDL, LDL particle size, plasma Lp-PLA2 activity, and PBMC enzyme activity in the whole-grain group were significantly different from those in the control group before and after adjusting for baseline levels. The PBMC levels of L-leucine, oleamide, lysoPC (16:0), and lysoPC (18:0) in the whole-grain group showed greater reductions compared with those of the control group. Changes in plasma metabolites were not significantly different between the two groups. Changes in PBMC Lp-PLA2 activity positively correlated with changes in L-leucine, oleamide, lysoPC (16:0), lysoPC (18:0), glucose, and ox-LDL, and negatively correlated with changes in LDL particle size. Conclusions This study showed that dietary intervention in prediabetic or type-2 diabetic patients had a greater effect on PBMC Lp-PLA2 activity and metabolites compared with those of plasma metabolites. Trial registration NCT02191644

KEYWORDS

Metabolites, Peripheral blood mononuclear cells, Prediabetes, Whole-grains and legumes

Title

Replacing carbohydrate with protein and fat in prediabetes or type-2 diabetes: greater effect on metabolites in PBMC than plasma

Author

Minjoo Kim, Gayoung Song, Miso Kang, Hye Jin Yoo, Tae-Sook Jeong, Sang-Hyun Lee, and Jong Ho Lee

Publish date

2016;

PMID

26175501

Abstract

MicroRNAs (miRNAs) play a significant role in ischemic heart disease. Animal models of left ventricular (LV) ischemia demonstrate a unique miRNA profile; however, these models have limitations in describing human disease. In this study, we performed next-generation miRNA and mRNA sequencing on LV tissue from nine patients undergoing cardiac surgery with cardiopulmonary bypass and cardioplegic arrest. Samples were obtained immediately after aortic cross clamping (baseline) and before aortic cross clamp removal (postischemic). Of 1,237 identified miRNAs, 21 were differentially expressed between baseline and postischemic LV samples including the upregulated miRNAs miR-339-5p and miR-483-3p and the downregulated miRNA miR-139-5p. Target prediction analysis of these miRNAs was integrated with mRNA expression from the same LV samples to identify anticorrelated miRNA-mRNA pairs. Gene enrichment studies of candidate mRNA targets demonstrated an association with cardiovascular disease, cell death, and metabolism. Therapeutics that intervene on these miRNAs and their downstream targets may lead to novel mechanisms of mitigating the damage caused by ischemic insults on the human heart.

KEYWORDS

microRNA, myocardial infarction, mRNA, sequencing

Title

Integrated microRNA and mRNA responses to acute human left ventricular ischemia

Author

Louis A. Saddic,1 Tzuu-Wang Chang,1 Martin I. Sigurdsson,1 Mahyar Heydarpour,1 Benjamin A. Raby,2 Stanton K. Shernan,1 Sary F. Aranki,3 Simon C. Body,1 and Jochen D. Muehlschlegelcorresponding author1

Publish date

2015 Oct;